Literature DB >> 21779431

Transcriptional Regulation of CRD-BP by c-myc: Implications for c-myc Functions.

Felicite K Noubissi1, Mikhail A Nikiforov, Nancy Colburn, Vladimir S Spiegelman.   

Abstract

The coding region determinant binding protein, CRD-BP, is a multifunctional RNA binding protein involved in different processes such as mRNA turnover, translation control, and localization. It is mostly expressed in fetal and neonatal tissues, where it regulates many transcripts essential for normal embryonic development. CRD-BP is scarce or absent in normal adult tissues but reactivated and/or overexpressed in various neoplastic and preneoplastic tumors and in most cell lines. Its expression has been associated with the most aggressive form of some cancers. CRD-BP is an important regulator of different genes including a variety of oncogenes or proto-oncogenes (c-myc, β-TrCP1, GLI1, etc.). Regulation of CRD-BP expression is critical for proper control of its targets as its overexpression may play an important role in abnormal cell proliferation, suppression of apoptosis, invasion, and metastasis. Molecular bases of the regulatory mechanisms governing CRD-BP expression are still not completely elucidated. In this article, we have identified c-myc as a novel transcriptional regulator of CRD-BP. We show that c-myc binds to CRD-BP promoter and induces its transcription. This induction of CRD-BP expression contributes to the role of c-myc in the regulation of translation, increase in cell size, and acceleration of cell cycle progression via a mechanism involving upregulation of β-TrCP1 levels and activities and accelerated degradation of PDCD4.

Entities:  

Keywords:  CRD-BP; PDCD4; c-myc; protein translation; β-TrCP1

Year:  2010        PMID: 21779431      PMCID: PMC3092266          DOI: 10.1177/1947601910395581

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  41 in total

1.  Secondary structure in the 5'-leader or 3'-untranslated region reduces protein yield but does not affect the functional interaction between the 5'-cap and the poly(A) tail.

Authors:  M Niepel; J Ling; D R Gallie
Journal:  FEBS Lett       Date:  1999-11-26       Impact factor: 4.124

2.  Overexpression of an mRNA-binding protein in human colorectal cancer.

Authors:  J Ross; I Lemm; B Berberet
Journal:  Oncogene       Date:  2001-10-04       Impact factor: 9.867

Review 3.  A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking.

Authors:  F C Nielsen; J Nielsen; J Christiansen
Journal:  Scand J Clin Lab Invest Suppl       Date:  2001

4.  Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein.

Authors:  G A Doyle; J M Bourdeau-Heller; S Coulthard; L F Meisner; J Ross
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

5.  Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro.

Authors:  P Leeds; B T Kren; J M Boylan; N A Betz; C J Steer; P A Gruppuso; J Ross
Journal:  Oncogene       Date:  1997-03-20       Impact factor: 9.867

6.  C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and malignant mesenchymal tumors.

Authors:  P Ioannidis; T Trangas; E Dimitriadis; M Samiotaki; I Kyriazoglou; C M Tsiapalis; C Kittas; N Agnantis; F C Nielsen; J Nielsen; J Christiansen; N Pandis
Journal:  Int J Cancer       Date:  2001-11       Impact factor: 7.396

7.  A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation.

Authors:  H S Yang; A P Jansen; R Nair; K Shibahara; A K Verma; J L Cmarik; N H Colburn
Journal:  Oncogene       Date:  2001-02-08       Impact factor: 9.867

8.  c-Myc enhances protein synthesis and cell size during B lymphocyte development.

Authors:  B M Iritani; R N Eisenman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 9.  The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis.

Authors:  Karina Yaniv; Joel K Yisraeli
Journal:  Gene       Date:  2002-04-03       Impact factor: 3.688

10.  Inhibition of HOS expression and activities by Wnt pathway.

Authors:  Vladimir S Spiegelman; Weigang Tang; Masaru Katoh; Thomas J Slaga; Serge Y Fuchs
Journal:  Oncogene       Date:  2002-01-24       Impact factor: 9.867

View more
  17 in total

Review 1.  Whisper mutations: cryptic messages within the genetic code.

Authors:  R Fåhraeus; M Marin; V Olivares-Illana
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

2.  DNA·RNA triple helix formation can function as a cis-acting regulatory mechanism at the human β-globin locus.

Authors:  Zhuo Zhou; Keith E Giles; Gary Felsenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-13       Impact factor: 11.205

3.  Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors.

Authors:  TaeWon Kim; Thomas Havighurst; KyungMann Kim; Mark Albertini; Yaohui G Xu; Vladimir S Spiegelman
Journal:  Mol Carcinog       Date:  2018-02-05       Impact factor: 4.784

4.  RNA-Binding Protein IGF2BP1 in Cutaneous Squamous Cell Carcinoma.

Authors:  TaeWon Kim; Thomas Havighurst; KyungMann Kim; Scott J Hebbring; Zhan Ye; Juliet Aylward; Sunduz Keles; Yaohui G Xu; Vladimir S Spiegelman
Journal:  J Invest Dermatol       Date:  2016-11-14       Impact factor: 8.551

5.  Two Isoforms of the RNA Binding Protein, Coding Region Determinant-binding Protein (CRD-BP/IGF2BP1), Are Expressed in Breast Epithelium and Support Clonogenic Growth of Breast Tumor Cells.

Authors:  Saja A Fakhraldeen; Rod J Clark; Avtar Roopra; Emily N Chin; Wei Huang; John Castorino; Kari B Wisinski; TaeWon Kim; Vladimir S Spiegelman; Caroline M Alexander
Journal:  J Biol Chem       Date:  2015-04-10       Impact factor: 5.157

6.  SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.

Authors:  Kazuyuki Matsushita; Toshiko Kajiwara; Mai Tamura; Mamoru Satoh; Nobuko Tanaka; Takeshi Tomonaga; Hisahiro Matsubara; Hideaki Shimada; Rei Yoshimoto; Akihiro Ito; Shuji Kubo; Tohru Natsume; David Levens; Minoru Yoshida; Fumio Nomura
Journal:  Mol Cancer Res       Date:  2012-04-11       Impact factor: 5.852

7.  IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2.

Authors:  Florian Sperling; Danny Misiak; Stefan Hüttelmaier; Patrick Michl; Heidi Griesmann
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

8.  Involvement of the mRNA binding protein CRD-BP in the regulation of metastatic melanoma cell proliferation and invasion by hypoxia.

Authors:  Evisabel A Craig; Jonathan D Weber; Vladimir S Spiegelman
Journal:  J Cell Sci       Date:  2012-10-04       Impact factor: 5.285

9.  High-throughput fluorescence anisotropy screen for inhibitors of the oncogenic mRNA binding protein, IMP-1.

Authors:  Lily Mahapatra; Chengjian Mao; Neal Andruska; Chen Zhang; David J Shapiro
Journal:  J Biomol Screen       Date:  2013-10-09

10.  Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon.

Authors:  Kathryn E Hamilton; Priya Chatterji; Emma T Lundsmith; Sarah F Andres; Veronique Giroux; Philip D Hicks; Felicite K Noubissi; Vladimir S Spiegelman; Anil K Rustgi
Journal:  Mol Cancer Res       Date:  2015-07-20       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.